Sparsentan in patients with IgA nephropathy: a prespecified …
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext
WebApr 1, 2023 · Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods.
DA: 1 PA: 18 MOZ Rank: 78